According to Reuters, GM (GM) is expected to post a huge loss. Reuters reports that oil company profits rose, but Exxon (XOM) missed its numbers. Reuters reported that stressed banks borrowed a…
Another biotech giant is biting the dust via a buyout offer. ImClone Systems Inc. (NASDAQ: IMCL) has been given a buyout offer from Bristol-Myers (NYSE: BMY) at $60.00 per share. As per…
Douglas A. McIntyre ImClone Systems Incorporated (NASDAQ: IMCL) has just announced that ERBITUX(R) has received marketing authorization in Japan for use in treating patients with advanced or metastatic colorectal cancer (mCRC). This approval will allow…
Douglas A. McIntyre If you thought this was a bad day for the market with the DJIA trading well under that 12,000 psychological level, there were some 400 stocks that hit 52-week lows today when…
These are ten of the analyst calls we are focusing on this Wednesday morning in pre-market trading: Bristol-Myers (NYSE: BMY) cut to Neutral at Cowen. Marriott (NYSE: MAR) cut to Perform at…
Bristol-Myers Squibb (NYSE: BMY) has submitted an open shelf offering today for an undetermined amount. The offering includes a combination of debt securities, preferred stock, depositary shares, common stock, and warrants to…
Douglas A. McIntyre Bristol-Myers Squibb Company (NYSE: BMY) came out with earnings at $0.35 EPS and reaffirmed 2008 guidance of $1.36 to $1.46 GAAP EPS and $1.60 to $1.70 non-GAAP EPS. It also maintained a…
Douglas A. McIntyre Medarex, Inc. (NASDAQ: MEDX) wants to clarify a few issues regarding the study halt from Pfizer (NYSE: PFE) this week on advanced melanoma. The company says that there are key differences between…
Bristol-Myers (NYSE: BMY) does not see much future in baby food. It is trying to sell its operation to a company where its is a better fit. According to the FT, that…
Those rummaging through the garbage of 52-week low lists are usually bottom-fishing investors or desperate CEOs. But, the list is so broad that it has become a tableau of the market as…
Some large companies, like Bristol-Myers (BMY), has already said that auction-rate securities on their balance sheets may have to be written down now that the market for this paper is illiquid. The…
Douglas A. McIntyre CyDex Pharmaceuticals, Inc. has filed to come public via an IPO in what it lists for filing purposes as up to $50 million in securities sales. It has applied to have the…
On tonight’s MAD MONEY on CNBC, Jim Cramer wanted to look for stocks with both appreciation potential that also offer capital preservation. He, just like us, believes we are starting to price…
Early this week we are running a list of stocks that have been in a turnaround plan, yet the stocks and the businesses haven’t turned around. Could these be the stocks to…
Medarex inc. (NASDAQ: MEDX) is seeing shares slapped in after-hours trading after the company is issuing disappointing news over the hopes for its Ipilimumab Pivotal Trials in patients with Advanced Metastatic Melanoma. …